New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
07:56 EDTGILD, MRK, IDIXGilead weakness creates buying opportunity, says RBC Capital
After Gilead's (GILD) stock fell following Merck's (MRK) acquisition of Idenix (IDIX), RBC Capital expects Sovaldi sales to come in well above consensus estimates for 2015, potentially enabling Gilead's EPS to reach $8-$10. RBC Capital says that the market expects the sales of HCV treatments to drop significantly in 2016, but the firm does not agree with this outlook. RBC Capital keeps an Outperform rating on Gilead.
News For GILD;MRK;IDIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 14, 2014
11:23 EDTMRKBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:10 EDTGILDGilead weakness today overdone, says Deutsche Bank
Subscribe for More Information
10:51 EDTGILDGilead weakness a buying opportunity, says RBC Capital
Subscribe for More Information
10:41 EDTGILDGilead weakness a buying opportunity, says RBC Capital
Subscribe for More Information
10:11 EDTGILDGilead volatility increases on wide price movement
Subscribe for More Information
10:05 EDTGILDAbbVie could cause Hep C price tipping point with aggressive pricing, WSJ says
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
09:14 EDTGILDJ&J sees FY14 pre-tax operating margin significantly improved vs. FY13
Subscribe for More Information
October 13, 2014
16:02 EDTGILDOptions Update; October 13, 2014
iPath S&P 500 VIX Short-Term Futures up 3.71 to 39.56. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX SUNE GILD BAC PBR according to Track Data.
09:56 EDTGILDBernstein biotech analyst to hold an analyst/industry conference call
Subscribe for More Information
08:36 EDTGILDGilead HARVONI launch should be strong, says BMO Capital
Subscribe for More Information
07:56 EDTGILDGilead Harvoni pricing 'very reasonable,' says RBC Capital
Subscribe for More Information
07:39 EDTGILDPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
07:37 EDTMRKAmerican Society of Anesthesiologists to hold annual meeting
Subscribe for More Information
October 10, 2014
14:08 EDTGILDGilead 12-week regimen of Harvoni to cost $94.5K
Gilead said its newly-approved treatment of hepatitis C genotype 1 infection, Harvoni, will be priced at $94,500 for a full 12 week regiment, according to multiple media outlets, which cite a company spokesperson.
13:55 EDTGILDGilead confirms FDA approval of Harvoni
Subscribe for More Information
13:42 EDTGILDGilead hepatitis C treatment Harvoni approved by FDA
The FDA announced the approval of Harvoni to treat chronic hepatitis C virus genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection, the agency stated. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection, it added. Harvoni is marketed by Gilead.
13:40 EDTGILDFDA approves Gilead hepatitus C treatment Harvoni
Subscribe for More Information
08:19 EDTGILDMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
07:21 EDTGILDFDA PDUFA Date for Gilead Sciences Sofosbuvir is October 10, 2014
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use